decisionhealth Newsletters, Coder Pink Sheets - 2008 Issue 2 (February)
Genentech agrees to make Avastin available through indirect shipping arrangements
Subscribe or sign in to view the full article.
Article Overview
This article covers a change in how Avastin can be obtained for ophthalmology use, following discussions involving Genentech and major eye organizations. It discusses the broader context of off-label prescribing, FDA approval status, drug distribution logistics, and an ongoing comparative study referenced by the National Eye Institute. The piece is relevant to ophthalmologists, retina specialists, pharmacy and compliance stakeholders, and coding/billing professionals tracking ophthalmology-related policy and drug access issues.
Why This Topic Matters
Access and distribution changes can affect how ophthalmologists obtain therapy for wet AMD and how practices coordinate with pharmacies, wholesalers, and legal counsel. The article also highlights the intersection of manufacturer policy, off-label prescribing, and specialty-society advocacy.
What You Will Learn
- How a manufacturer distribution change affects access to a commonly used ophthalmic drug
- The roles of ophthalmology specialty organizations in addressing drug access
- The relationship between FDA approval, off-label prescribing, and ophthalmic treatment access
- Why legal and state-level considerations may matter for indirect shipping arrangements
- The general context of a comparative study of two drugs in age-related macular degeneration
Who Should Read This
- Ophthalmologists
- Retina specialists
- Medical practice administrators
- Pharmacy and compounding stakeholders
- Compliance and legal advisors
- Medical coders and billing staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com